|Assessment Status||Rapid Review Complete|
|Indication||In combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of the first-line treatment of metastatic squamous non-small cell lung carcinoma.|
|Rapid review commissioned||25/02/2019|
|Rapid review completed||25/03/2019|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with carboplatin and either paclitaxel or nab-P compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations – February 2021.